SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cannex Capital Holdings Inc. – ‘40FR12G’ on 7/16/19 – ‘EX-99.113’

On:  Tuesday, 7/16/19, at 5:04pm ET   ·   Accession #:  1062993-19-2929   ·   File #:  0-56073

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/16/19  Cannex Capital Holdings Inc.      40FR12G              138:29M                                    Newsfile Corp/FA

Registration of Securities of a Canadian Issuer   —   Form 40-F   —   Sect. 12(g) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 40FR12G     Registration of Securities of a Canadian Issuer     HTML    112K 
 2: EX-99.1     Miscellaneous Exhibit -- exhibit99-1                HTML     53K 
11: EX-99.10    Miscellaneous Exhibit -- exhibit99-10               HTML     30K 
101: EX-99.100   Miscellaneous Exhibit -- exhibit99-100              HTML     49K  
102: EX-99.101   Miscellaneous Exhibit -- exhibit99-101              HTML    872K  
103: EX-99.102   Miscellaneous Exhibit -- exhibit99-102              HTML     78K  
104: EX-99.103   Miscellaneous Exhibit -- exhibit99-103              HTML     70K  
105: EX-99.104   Miscellaneous Exhibit -- exhibit99-104              HTML     35K  
106: EX-99.105   Miscellaneous Exhibit -- exhibit99-105              HTML   2.88M  
107: EX-99.106   Miscellaneous Exhibit -- exhibit99-106              HTML     34K  
108: EX-99.107   Miscellaneous Exhibit -- exhibit99-107              HTML     33K  
109: EX-99.108   Miscellaneous Exhibit -- exhibit99-108              HTML     39K  
110: EX-99.109   Miscellaneous Exhibit -- exhibit99-109              HTML    290K  
12: EX-99.11    Miscellaneous Exhibit -- exhibit99-11               HTML    156K 
111: EX-99.110   Miscellaneous Exhibit -- exhibit99-110              HTML    133K  
112: EX-99.111   Miscellaneous Exhibit -- exhibit99-111              HTML     33K  
113: EX-99.112   Miscellaneous Exhibit -- exhibit99-112              HTML     33K  
114: EX-99.113   Miscellaneous Exhibit -- exhibit99-113              HTML     42K  
115: EX-99.114   Miscellaneous Exhibit -- exhibit99-114              HTML     32K  
116: EX-99.115   Miscellaneous Exhibit -- exhibit99-115              HTML     39K  
117: EX-99.116   Miscellaneous Exhibit -- exhibit99-116              HTML     34K  
118: EX-99.117   Miscellaneous Exhibit -- exhibit99-117              HTML     37K  
119: EX-99.118   Miscellaneous Exhibit -- exhibit99-118              HTML    455K  
120: EX-99.119   Miscellaneous Exhibit -- exhibit99-119              HTML    133K  
13: EX-99.12    Miscellaneous Exhibit -- exhibit99-12               HTML     30K 
121: EX-99.120   Miscellaneous Exhibit -- exhibit99-120              HTML     33K  
122: EX-99.121   Miscellaneous Exhibit -- exhibit99-121              HTML     33K  
123: EX-99.122   Miscellaneous Exhibit -- exhibit99-122              HTML     41K  
124: EX-99.123   Miscellaneous Exhibit -- exhibit99-123              HTML     36K  
125: EX-99.124   Miscellaneous Exhibit -- exhibit99-124              HTML    491K  
126: EX-99.125   Miscellaneous Exhibit -- exhibit99-125              HTML    140K  
127: EX-99.126   Miscellaneous Exhibit -- exhibit99-126              HTML     33K  
128: EX-99.127   Miscellaneous Exhibit -- exhibit99-127              HTML     33K  
129: EX-99.128   Miscellaneous Exhibit -- exhibit99-128              HTML     30K  
130: EX-99.129   Miscellaneous Exhibit -- exhibit99-129              HTML    492K  
14: EX-99.13    Miscellaneous Exhibit -- exhibit99-13               HTML     32K 
131: EX-99.130   Miscellaneous Exhibit -- exhibit99-130              HTML    143K  
132: EX-99.131   Miscellaneous Exhibit -- exhibit99-131              HTML     32K  
133: EX-99.132   Miscellaneous Exhibit -- exhibit99-132              HTML     32K  
134: EX-99.133   Miscellaneous Exhibit -- exhibit99-133              HTML     30K  
135: EX-99.134   Miscellaneous Exhibit -- exhibit99-134              HTML     69K  
136: EX-99.135   Miscellaneous Exhibit -- exhibit99-135              HTML     31K  
137: EX-99.136   Miscellaneous Exhibit -- exhibit99-136              HTML     29K  
138: EX-99.137   Miscellaneous Exhibit -- exhibit99-137              HTML     30K  
15: EX-99.14    Miscellaneous Exhibit -- exhibit99-14               HTML     32K 
16: EX-99.15    Miscellaneous Exhibit -- exhibit99-15               HTML     32K 
17: EX-99.16    Miscellaneous Exhibit -- exhibit99-16               HTML     33K 
18: EX-99.17    Miscellaneous Exhibit -- exhibit99-17               HTML     34K 
19: EX-99.18    Miscellaneous Exhibit -- exhibit99-18               HTML     42K 
20: EX-99.19    Miscellaneous Exhibit -- exhibit99-19               HTML     33K 
 3: EX-99.2     Miscellaneous Exhibit -- exhibit99-2                HTML     31K 
21: EX-99.20    Miscellaneous Exhibit -- exhibit99-20               HTML     45K 
22: EX-99.21    Miscellaneous Exhibit -- exhibit99-21               HTML    145K 
23: EX-99.22    Miscellaneous Exhibit -- exhibit99-22               HTML     77K 
24: EX-99.23    Miscellaneous Exhibit -- exhibit99-23               HTML     32K 
25: EX-99.24    Miscellaneous Exhibit -- exhibit99-24               HTML     32K 
26: EX-99.25    Miscellaneous Exhibit -- exhibit99-25               HTML     35K 
27: EX-99.26    Miscellaneous Exhibit -- exhibit99-26               HTML     28K 
28: EX-99.27    Miscellaneous Exhibit -- exhibit99-27               HTML     38K 
29: EX-99.28    Miscellaneous Exhibit -- exhibit99-28               HTML     34K 
30: EX-99.29    Miscellaneous Exhibit -- exhibit99-29               HTML    782K 
 4: EX-99.3     Miscellaneous Exhibit -- exhibit99-3                HTML     28K 
31: EX-99.30    Miscellaneous Exhibit -- exhibit99-30               HTML     30K 
32: EX-99.31    Miscellaneous Exhibit -- exhibit99-31               HTML     49K 
33: EX-99.32    Miscellaneous Exhibit -- exhibit99-32               HTML     31K 
34: EX-99.33    Miscellaneous Exhibit -- exhibit99-33               HTML     51K 
35: EX-99.34    Miscellaneous Exhibit -- exhibit99-34               HTML     35K 
36: EX-99.35    Miscellaneous Exhibit -- exhibit99-35               HTML     36K 
37: EX-99.36    Miscellaneous Exhibit -- exhibit99-36               HTML     42K 
38: EX-99.37    Miscellaneous Exhibit -- exhibit99-37               HTML     36K 
39: EX-99.38    Miscellaneous Exhibit -- exhibit99-38               HTML     38K 
40: EX-99.39    Miscellaneous Exhibit -- exhibit99-39               HTML     35K 
 5: EX-99.4     Miscellaneous Exhibit -- exhibit99-4                HTML     30K 
41: EX-99.40    Miscellaneous Exhibit -- exhibit99-40               HTML     35K 
42: EX-99.41    Miscellaneous Exhibit -- exhibit99-41               HTML     35K 
43: EX-99.42    Miscellaneous Exhibit -- exhibit99-42               HTML     35K 
44: EX-99.43    Miscellaneous Exhibit -- exhibit99-43               HTML     36K 
45: EX-99.44    Miscellaneous Exhibit -- exhibit99-44               HTML     31K 
46: EX-99.45    Miscellaneous Exhibit -- exhibit99-45               HTML     28K 
47: EX-99.46    Miscellaneous Exhibit -- exhibit99-46               HTML    454K 
48: EX-99.47    Miscellaneous Exhibit -- exhibit99-47               HTML     29K 
49: EX-99.48    Miscellaneous Exhibit -- exhibit99-48               HTML    114K 
50: EX-99.49    Miscellaneous Exhibit -- exhibit99-49               HTML     33K 
 6: EX-99.5     Miscellaneous Exhibit -- exhibit99-5                HTML   1.56M 
51: EX-99.50    Miscellaneous Exhibit -- exhibit99-50               HTML     33K 
52: EX-99.51    Miscellaneous Exhibit -- exhibit99-51               HTML     49K 
53: EX-99.52    Miscellaneous Exhibit -- exhibit99-52               HTML     31K 
54: EX-99.53    Miscellaneous Exhibit -- exhibit99-53               HTML     44K 
55: EX-99.54    Miscellaneous Exhibit -- exhibit99-54               HTML     31K 
56: EX-99.55    Miscellaneous Exhibit -- exhibit99-55               HTML    297K 
57: EX-99.56    Miscellaneous Exhibit -- exhibit99-56               HTML    101K 
58: EX-99.57    Miscellaneous Exhibit -- exhibit99-57               HTML     33K 
59: EX-99.58    Miscellaneous Exhibit -- exhibit99-58               HTML     33K 
60: EX-99.59    Miscellaneous Exhibit -- exhibit99-59               HTML     37K 
 7: EX-99.6     Miscellaneous Exhibit -- exhibit99-6                HTML    499K 
61: EX-99.60    Miscellaneous Exhibit -- exhibit99-60               HTML     34K 
62: EX-99.61    Miscellaneous Exhibit -- exhibit99-61               HTML     31K 
63: EX-99.62    Miscellaneous Exhibit -- exhibit99-62               HTML     33K 
64: EX-99.63    Miscellaneous Exhibit -- exhibit99-63               HTML     35K 
65: EX-99.64    Miscellaneous Exhibit -- exhibit99-64               HTML     33K 
66: EX-99.65    Miscellaneous Exhibit -- exhibit99-65               HTML     36K 
67: EX-99.66    Miscellaneous Exhibit -- exhibit99-66               HTML     37K 
68: EX-99.67    Miscellaneous Exhibit -- exhibit99-67               HTML     37K 
69: EX-99.68    Miscellaneous Exhibit -- exhibit99-68               HTML     31K 
70: EX-99.69    Miscellaneous Exhibit -- exhibit99-69               HTML     37K 
 8: EX-99.7     Miscellaneous Exhibit -- exhibit99-7                HTML    155K 
71: EX-99.70    Miscellaneous Exhibit -- exhibit99-70               HTML     33K 
72: EX-99.71    Miscellaneous Exhibit -- exhibit99-71               HTML     30K 
73: EX-99.72    Miscellaneous Exhibit -- exhibit99-72               HTML     32K 
74: EX-99.73    Miscellaneous Exhibit -- exhibit99-73               HTML    177K 
75: EX-99.74    Miscellaneous Exhibit -- exhibit99-74               HTML     37K 
76: EX-99.75    Miscellaneous Exhibit -- exhibit99-75               HTML     35K 
77: EX-99.76    Miscellaneous Exhibit -- exhibit99-76               HTML    159K 
78: EX-99.77    Miscellaneous Exhibit -- exhibit99-77               HTML    160K 
79: EX-99.78    Miscellaneous Exhibit -- exhibit99-78               HTML     42K 
80: EX-99.79    Miscellaneous Exhibit -- exhibit99-79               HTML     35K 
 9: EX-99.8     Miscellaneous Exhibit -- exhibit99-8                HTML     75K 
81: EX-99.80    Miscellaneous Exhibit -- exhibit99-80               HTML     35K 
82: EX-99.81    Miscellaneous Exhibit -- exhibit99-81               HTML    588K 
83: EX-99.82    Miscellaneous Exhibit -- exhibit99-82               HTML     46K 
84: EX-99.83    Miscellaneous Exhibit -- exhibit99-83               HTML     50K 
85: EX-99.84    Miscellaneous Exhibit -- exhibit99-84               HTML     47K 
86: EX-99.85    Miscellaneous Exhibit -- exhibit99-85               HTML     35K 
87: EX-99.86    Miscellaneous Exhibit -- exhibit99-86               HTML    355K 
88: EX-99.87    Miscellaneous Exhibit -- exhibit99-87               HTML    130K 
89: EX-99.88    Miscellaneous Exhibit -- exhibit99-88               HTML     33K 
90: EX-99.89    Miscellaneous Exhibit -- exhibit99-89               HTML     33K 
10: EX-99.9     Miscellaneous Exhibit -- exhibit99-9                HTML     32K 
91: EX-99.90    Miscellaneous Exhibit -- exhibit99-90               HTML     37K 
92: EX-99.91    Miscellaneous Exhibit -- exhibit99-91               HTML     35K 
93: EX-99.92    Miscellaneous Exhibit -- exhibit99-92               HTML     39K 
94: EX-99.93    Miscellaneous Exhibit -- exhibit99-93               HTML     35K 
95: EX-99.94    Miscellaneous Exhibit -- exhibit99-94               HTML     59K 
96: EX-99.95    Miscellaneous Exhibit -- exhibit99-95               HTML     35K 
97: EX-99.96    Miscellaneous Exhibit -- exhibit99-96               HTML     42K 
98: EX-99.97    Miscellaneous Exhibit -- exhibit99-97               HTML     31K 
99: EX-99.98    Miscellaneous Exhibit -- exhibit99-98               HTML     39K 
100: EX-99.99    Miscellaneous Exhibit -- exhibit99-99               HTML     48K  


‘EX-99.113’   —   Miscellaneous Exhibit — exhibit99-113


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  Cannex Capital Holdings Inc. - Exhibit 99.113 - Filed by newsfilecorp.com  
 <> 

CANNEX SECURITYHOLDERS FORMALLY APPROVE 4FRONT AGREEMENT,
CSE GRANTS CONDITIONAL APPROVAL, TRADING TO RESUME, AND UPDATE
ON THE CLOSING OF THE BUSINESS COMBINATION WITH 4FRONT

Closing of the Business Combination will require consent from U.S. federal antitrust regulators,
final court approval of the Plan of Arrangement, and final approval by the CSE

Vancouver, BC, April 26, 2019 – Cannex Capital Holdings Inc. (CSE: CNNX)(OTCQX: CNXXF) (“Cannex” or the “Company”) is pleased to announce that securityholders of Cannex have voted overwhelmingly in favour of the business combination (the “Transaction”) with 4Front Holdings, LLC (“4Front”) at a special meeting of securityholders (the “Meeting”) of Cannex held on April 18, 2019. Additional information on the Transaction can be found in the management information circular of Cannex dated March 19, 2019, which is available under Cannex’s SEDAR profile at www.sedar.com.

The Transaction, whereby the former securityholders of Cannex and 4Front will become securityholders in the combined company (the “Resulting Issuer”), was approved by 99.97% of holders of common shares of Cannex, 100% of holders of Class A convertible restricted voting shares of Cannex and 100% of the holders of senior convertible notes of Cannex who voted at the Meeting. Cannex will post the voting results under its SEDAR profile.

“We have cleared significant hurdles associated with our business combination with 4Front. Even though the voting agreements had us confident in the outcome of the shareholder vote, 99.97% is a great confirmation on the merits of our merger and its terms for Cannex shareholders,” said Anthony Dutton, CEO of Cannex.

CSE Grants Conditional Approval and to Lift Halt on Stock

The Company is also pleased to announce that the Canadian Securities Exchange (the “CSE”) has conditionally approved the resulting issuer for listing, and will lift the trading halt on April 29th, 2019. Trading will continue as Cannex until the transaction has been completed, at which time the CSE will issue a bulletin announcing the listing of 4Front Ventures Corp.

Update on Business Combination with 4Front

Pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”), as amended, Cannex and 4Front were required to file a pre-Transaction notification to federal antitrust authorities and must observe a waiting period before completing the Transaction. As part of the HSR Act review process, Cannex and 4Front received a request for additional information (the "Second Request") from the US Department of Justice Antitrust Division on April 18, 2019. The Second Request extends the HSR Act waiting period for up to 30 days after Cannex and 4Front have each substantially complied with the Second Request.

Cannex and 4Front are working to substantially comply with the Second Request as quickly as feasible. Based on other recent business combinations within the cannabis space, numerous larger competitors of the combined companies in North America, and limited geographic and business overlap of the companies, both Cannex and 4Front believe that the Transaction does not raise substantial competitive concerns, and that it will enhance competition in nascent markets.

“4Front’s confidence in the benefits of partnering with Cannex have only grown, which is not always the case when navigating months of detailed administrative work and the corresponding issues that surface,” said Josh Rosen, CEO of 4Front.

       
Cannex Capital www.cannexcapital.com info@cannexcapital.com 604 628 9338


Closing of the Transaction remains subject to resolving the Second Request, final regulatory approval, and other customary completion conditions. Upon receipt of such regulatory approval and satisfaction or waiver of all other completion conditions, Cannex and 4Front will make an application to the Supreme Court of British Columbia for the final order in respect of the Transaction. A news release will follow when a hearing of the application for the final order in respect of the Transaction has been scheduled.

About Cannex Capital Holdings Inc.

Cannex, through its wholly-owned subsidiaries, provides a wide range of services including real estate, management, financial, branding and IP to licensed cannabis business operators domestically and internationally. Cannex is focused on premium indoor cultivation, extraction, manufacturing and branding of edible and derivative products as well as retail operations. Cannex is undertaking expansion initiatives to support the acquisition and development of additional assets in legal medical and recreational cannabis markets. Based in Vancouver, BC, Cannex is managed by a team of experienced industry and capital markets experts who are committed to aggressive, cost-effective growth. Cannex currently owns BrightLeaf Development LLC which holds real estate assets, property leases, brands and intellectual property, and material supply agreements with Superior Gardens LLC (d/b/a Northwest Cannabis Solutions), Washington State’s and the Pacific Northwest’s largest full-line cannabis producer/processor, as well as 7Point Holdings LLC, another Washington State licensed cannabis producer/processor. Northwest Cannabis Solutions and 7Point Holdings are not Cannex subsidiaries, and Cannex does not hold any ownership position in either company.

About 4Front Holdings, LLC

4Front is building a next-generation company in the cannabis industry, based upon strategic and aligned leadership, battle-tested operating capabilities, transparent and principled governance, and a commitment to developing and supporting people and communities. Led by a group of professionals with experience in finance, real estate, manufacturing, distribution & logistics, multi-location retail & hospitality operations and talent development & retention, 4Front has invested heavily to assemble a comprehensive collection of management skills and hands-on operating expertise that can support the rapid operational growth opportunity being afforded by the increased legalization of cannabis across the globe. For more information, visit 4Front’s website. (www.4frontventures.com).

Cannex Capital Holdings Inc.
Anthony Dutton, CEO
(604) 649-7787
Email: adutton@cannexcapital.com
Website: www.cannexcapital.com
 
Media Contact for 4Front Holdings, LLC
Anne Donohoe / Nick Opich
KCSA Strategic Communications
adonohoe@kcsa.com / nopich@kcsa.com
212-896-1265 / 212-896-1206

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

2


This news release was prepared by management of Cannex, which takes full responsibility for its contents. The CSE has not reviewed and does not accept responsibility for the adequacy of this news release.

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Cannex’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements. These forward-looking statements include statements regarding the anticipated closing date of the lifting of the trading halt by the CSE, the ability of Cannex and 4Front to satisfy any competitive concerns raised in the HSR process, the ability of Cannex and 4Front to comply with the Second Request and obtain regulatory approval and satisfy or waive all closing conditions to the Transaction.

There can be no assurance that such forward-looking statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking statements. These forward-looking statements reflect the current beliefs of Cannex and are based on information currently available to Cannex and on assumptions that Cannex believes are reasonable. These assumptions include, but are not limited to, the anticipated closing date of the lifting of the trading halt by the CSE and the ability of Cannex and 4Front to obtain regulatory approval and satisfy or waive all closing conditions to the Transaction. Forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Resulting Issuer to be materially different from those expressed or implied by such forward-looking statements. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive regulatory approvals; failure to fulfill or waive any of the conditions precedent to the definitive agreement relating to the Transaction or failure to perform all the necessary steps with respect to the Transaction; the actual results of future operations compared to the forecasted results contained in the forward-looking statements; competition; changes in legislation affecting the Resulting Issuer; the timing and availability of external financing on acceptable terms; and other risk factors.

Cannex cautions that the foregoing list of material factors is not exhaustive. When relying on Cannex’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Cannex has assumed that the material factors referred to in the previous paragraph will not cause such forward- looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking information contained in this news release represents Cannex’s expectations as of the date of this news release and, accordingly, are subject to change after such date.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Cannex disclaims any intention or obligation to update or revise such information, except as required by applicable law.

3



Dates Referenced Herein

This ‘40FR12G’ Filing    Date    Other Filings
Filed on:7/16/19None on these Dates
4/26/19
4/18/19
3/19/19
 List all Filings 
Top
Filing Submission 0001062993-19-002929   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 16, 4:55:12.0pm ET